Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Oana Petrenciuc"'
Autor:
M. Luz, Mindaugas Jievaltas, Boris Alekseev, Aramis Investigators, Neal D. Shore, Toni Sarapohja, Sergey Polyakov, Iris Kuss, Karim Fizazi, Matthew R. Smith, Teuvo L Tammela, Marie-Aude Le Berre, Egils Vjaters, Amir Snapir, Oana Petrenciuc, Albertas Ulys
Publikováno v:
New England Journal of Medicine. 383:1040-1049
Darolutamide is a structurally distinct androgen-receptor inhibitor that is approved for the treatment of nonmetastatic, castration-resistant prostate cancer. In the planned primary analysis of a phase 3 trial, the median metastasis-free survival was
Autor:
Charles J. Ryan, Oana Petrenciuc, Daniel H. Shevrin, Emmanuel S. Antonarakis, Cindy Lu, Neeta Pandit-Taskar, Jorge A. Carrasquillo, Désirée Deandreis, Christopher Sweeney, Heather A. Jacene, Yohann Loriot, Michael J. Morris, Karim Fizazi, Celestia S. Higano, Hubert J. Vesselle
Publikováno v:
European journal of cancer (Oxford, England : 1990)
Purpose Radium 223 dichloride (radium-223) is an alpha particle–emitting bone-directed therapy that prolongs overall survival in men with bone-predominant metastatic castration-resistant prostate cancer (mCRPC). Docetaxel is an antimicrotubule cyto
Autor:
Sibylle Boehmer, Lars Franzén, Robert E. Coleman, Joe M. O'Sullivan, Rui Li, Steffen Wedel, Isabel Syndikus, John P Logue, Mihalj Seke, David Bottomley, Ales Chodacki, Oliver Sartor, Daniel Heinrich, Sophie D. Fosså, Nicholas D. James, Marcos F. Dall'Oglio, Paweł Wiechno, K. Staudacher, Sten Nilsson, Peter Hoskin, Arne Solberg, Nicholas J. Vogelzang, Oana Petrenciuc, Svein Inge Helle, Anders Widmark, Ján Kliment, Øyvind S. Bruland, Dag Clement Johannessen, Chris Parker
Publikováno v:
Parker, C C, Coleman, R E, Sartor, O, Vogelzang, N J, Bottomley, D, Heinrich, D, Helle, S I, O'Sullivan, J M, Fosså, S D, Chodacki, A, Wiechno, P, Logue, J, Seke, M, Widmark, A, Johannessen, D C, Hoskin, P, James, N D, Solberg, A, Syndikus, I, Kliment, J, Wedel, S, Boehmer, S, Dall'Oglio, M, Franzén, L, Bruland, Ø S, Petrenciuc, O, Staudacher, K, Li, R & Nilsson, S 2017, ' Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial ', European Urology, vol. 73, pp. 427-435 . https://doi.org/10.1016/j.eururo.2017.06.021
Repositório Institucional da USP (Biblioteca Digital da Produção Intelectual)
Universidade de São Paulo (USP)
instacron:USP
Translational Andrology and Urology
Parker, C C, Coleman, R E, Sartor, O, Vogelzang, N J, Bottomley, D, Heinrich, D, Helle, S I, O'Sullivan, J M, Fosså, S D, Chodacki, A, Wiechno, P, Logue, J, Seke, M, Widmark, A, Johannessen, D C, Hoskin, P, James, N D, Solberg, A, Syndikus, I, Kliment, J, Wedel, S, Boehmer, S, Dall'Oglio, M, Franzén, L, Bruland, Ø S, Petrenciuc, O, Staudacher, K, Li, R & Nilsson, S 2017, ' Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial ', European Urology . https://doi.org/10.1016/j.eururo.2017.06.021
Repositório Institucional da USP (Biblioteca Digital da Produção Intelectual)
Universidade de São Paulo (USP)
instacron:USP
Translational Andrology and Urology
Parker, C C, Coleman, R E, Sartor, O, Vogelzang, N J, Bottomley, D, Heinrich, D, Helle, S I, O'Sullivan, J M, Fosså, S D, Chodacki, A, Wiechno, P, Logue, J, Seke, M, Widmark, A, Johannessen, D C, Hoskin, P, James, N D, Solberg, A, Syndikus, I, Kliment, J, Wedel, S, Boehmer, S, Dall'Oglio, M, Franzén, L, Bruland, Ø S, Petrenciuc, O, Staudacher, K, Li, R & Nilsson, S 2017, ' Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial ', European Urology . https://doi.org/10.1016/j.eururo.2017.06.021
BACKGROUND: In Alpharadin in Symptomatic Prostate Cancer (ALSYMPCA) trial, radium-223 versus placebo prolonged overall survival with favorable safety in castration-resistant prostate cancer patients with symptomatic bone metastases. Long-term radium-
Autor:
Alan Brown, Andrei Iagaru, Oliver Sartor, Daniel Celestino Fernandez, Matthew R. Smith, Jeremy Gratt, Yu-Ning Wong, Neal D. Shore, Jose Lutzky, Michael J. Morris, Adam P. Dicker, Christopher Sweeney, Manish Agrawal, Nicholas J. Vogelzang, Oana Petrenciuc, Jorge A. Garcia, Fabio Almeida
Publikováno v:
The Oncologist. 23:193-202
Background In the phase III ALSYMPCA trial, metastatic castration-resistant prostate cancer (mCRPC) patients had few prior life-prolonging therapies. Following ALSYMPCA, which demonstrated radium-223 survival benefit, and before radium-223 U.S. comme
Autor:
Matthew R. Smith, Christian Zurth, Karim Fizazi, M-A. Le Berre, T Tammela, Iris Kuss, Oana Petrenciuc, N.D. Shore
Publikováno v:
Annals of Oncology. 31:S1327-S1328
Autor:
Shankar Srinivasan, Marie-Aude Le Berre, Teuvo L.J. Tammela, Karim Fizazi, Matthew R. Smith, Christopher Michael Pieczonka, Christian Zurth, Oana Petrenciuc, David L. Morris, Iris Kuss, Jeanny B. Aragon-Ching, Neal D. Shore
Publikováno v:
Journal of Clinical Oncology. 39:5079-5079
5079 Background: Patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) need therapy that prolongs survival with little added toxicity, thus preserving quality of life. The second-generation androgen receptor inhibitors (ARIs
Publikováno v:
Cancer Research. 77:OT1-04
Background: Bone-metastatic breast cancer (MBC) treatment is limited. In a phase 2a study of bone-dominant MBC patients, radium-223, a first-in-class α emitter with targeted cytotoxic effect on bone metastases (mets), reduced bone biomarker levels w
Autor:
M Campone, A. Zhang, A Barnadas, Hope S. Rugo, KC Drumea, Rui Li, Robert E. Coleman, Oana Petrenciuc
Publikováno v:
Cancer Research. 77:OT1-04
Background: Treatment options for bone-dominant metastatic breast cancer (MBC) are limited. Radium-223, a first-in-class α emitter with a targeted antitumor effect on bone metastases (mets), was well tolerated and reduced bone biomarker levels in a
Autor:
Olaf Prien, Iris Kuss, Kristina Graudenz, Karim Fizazi, Bart Ploeger, Gustavo Borghesi, Teuvo L.J. Tammela, Neal D. Shore, Robert Fricke, Jonathan Moss, Hille Gieschen, Oana Petrenciuc, Frank Verholen, Christian Zurth, Mikko Koskinen, Matthew R. Smith
Publikováno v:
Targeted Oncology
Background Darolutamide, an androgen receptor antagonist with a distinct molecular structure, significantly prolonged metastasis-free survival versus placebo in the phase III ARAMIS study in men with nonmetastatic castration-resistant prostate cancer
Autor:
G. Kenneth Jansz, Neal D. Shore, Paul Ouellette, Flavio Mavignier Carcano, Matthew R. Smith, Christian Kappeler, Sergio Lago, Manuel Philco Salas, Toni Sarapohja, Teuvo L.J. Tammela, Jose Jaime Correa, Larissa De Arruda, Nicolas Lazaretti, Karim Fizazi, Murilo Luz, Marc Pliskin, Oana Petrenciuc, Diogo Assed Bastos, Livia Andrade
Publikováno v:
Journal of Clinical Oncology. 39:240-240
240 Background: DARO is a structurally distinct androgen receptor inhibitor approved for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC) based on significantly prolonged metastasis-free survival compared with PBO (median